Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Viral Infection Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MBTPS1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MBTPS1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View MBTPS1 Products |
| Gene Delivery | MBTPS1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View MBTPS1 Products |
| Benchmark Ab | Anti-MBTPS1 (Sequence of PF-429242 control derivative) Recombinant positive control. |
View MBTPS1 Products |
| Validator | MBTPS1 siRNA Set For knockdown verification. |
View MBTPS1 Products |
| Related Target A | SREBF1 Downstream master transcription factor for lipid synthesis cleaved by MBTPS1. |
View SREBF1 Products |
| Related Target B | MBTPS2 Site-2 Protease; critical counter-screening target to ensure drug selectivity. |
View MBTPS2 Products |
| Related Target C | ATF6 Key endoplasmic reticulum stress sensor cleaved by MBTPS1 during UPR. |
View ATF6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Maintaining native autoproteolytic processing of MBTPS1 | HEK293 mammalian expression system guarantees correct folding and essential post-translational modifications. |
| Selectivity screening against related proteases (MBTPS2, PCSK9) | Sequence-verified recombinant homolog panel available with high purity (>95%) for cross-reactivity profiling. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live MBTPS1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MBTPS1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule inhibitors and RNA interference (RNAi) modalities. As first-generation therapies reach the clinic, the next wave of R&D is targeting highly selective, liver-targeted inhibition to treat metabolic dysfunction-associated steatohepatitis (MASH) and dyslipidemia while avoiding systemic osteochondrodysplasia risks.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Pfizer, Academic Institutions | MASH, Hyperlipidemia, Viral Infection (Lassa fever) | Enzymatic Activity Assays (Need active recombinant catalytic domain) |
| RNAi / siRNA | Alnylam, Arrowhead | Severe Dyslipidemia, Metabolic Syndrome | Target Knockdown Validation (Need validated siRNA controls and Lentivirus) |
| Monoclonal Antibody | Biotech Startups | Skeletal Dysplasia, Rare Bone Diseases | Epitope Mapping & Binding Kinetics (Need sequence-verified ECD-Fc protein) |